scholarly journals Analysis of aflatoxin B1-human serum albumin adducts by a sandwich enzyme-linked immunosorbent assay

1996 ◽  
Vol 1996 (43) ◽  
pp. 43-46 ◽  
Author(s):  
Osamu KAWAMURA ◽  
J.-M. LIM ◽  
Hiroki OKUMURA ◽  
Sigefumi KISHIMOTO ◽  
G. CHEN ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Immunosorbent Assay ◽  
Aflatoxin B1 ◽  
Enzyme Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay of Benomyl and Thiabendazole in Some Foods

1987 ◽  
Vol 70 (6) ◽  
pp. 1025-1027 ◽  
Author(s):  
Harvey W Newsome ◽  
Peter G Collins
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Ethyl Acetate ◽  
Human Serum ◽  
Immunosorbent Assay ◽  
Decomposition Product ◽  
Ethyl Acetate Extract ◽  
Enzyme Linked Immunosorbent Assay ◽  
Immunosorbent Assays ◽  
Lower Limits

Abstract Enzyme-linked immunosorbent assays were developed for benomyl as its decomposition product, methyl 2-benzimidazoIe carbamate, and thiabendazole in foods. Immunogens consisting of human serum albumin coupled to 2-succinamidobenzimidazole or 2-{2'-succinamido- 4'-thiazolyl)benzimidazole were used in rabbits to raise antisera that were specific for the respective fungicides. Lower limits of quantitation of 0.35 ppm for benomyl and 0.03 ppm for thiabendazole were established without cleanup of the ethyl acetate extract. Recoveries of benomyl from 3 crops spiked at 0.5 to 10 ppm averaged 89% (range 73-109%) and of thiabendazole from 5 crops spiked at 0.1 to 2.0 ppm were 93% (range 81-105%).

scholarly journals Determination of chemical-specific IgGs in serum by an enzyme-linked immunosorbent assay with partial peptides of human serum albumin

2018 ◽  
Vol 43 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Yasuhiro Ishihara ◽  
Nami Ikeda-Ishihara ◽  
Chihaya Koriyama ◽  
Noriaki Kakiuchi ◽  
Masayuki Tanaka ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay

Sandwich enzyme-linked immunosorbent assay for the quantification of human serum albumin fragment 408–423 in bodily fluids

2015 ◽  
Vol 476 ◽  
pp. 29-35 ◽  
Author(s):  
Katharina B. Mohr ◽  
Onofrio Zirafi ◽  
Mark Hennies ◽  
Sebastian Wiese ◽  
Frank Kirchhoff ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Bodily Fluids

scholarly journals Estimation of Group B Streptococcus Type III Polysaccharide-Specific Antibody Concentrations in Human Sera Is Antigen Dependent

1998 ◽  
Vol 66 (12) ◽  
pp. 5848-5853 ◽  
Author(s):  
Reva Bhushan ◽  
Bascom F. Anthony ◽  
Carl E. Frasch
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Conjugate Vaccine ◽  
Group B Streptococcus ◽  
Antigenic Specificity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Type Iii ◽  
Human Sera ◽  
Group B

ABSTRACT The presence of immunoglobulin G (IgG) antibodies against group B streptococcus (GBS) type III polysaccharide (PS) has been correlated with protection against GBS disease. The GBS type III PS is structurally similar to the pneumococcal type 14 PS, differing only in the presence of sialic acid residues. Four different preparations of GBS type III PS were evaluated for their specificity in enzyme-linked immunosorbent assay (ELISA): free PS, free PS mixed with methylated human serum albumin (mHSA), PS conjugated to biotin and PS conjugated to human serum albumin. Three groups of human sera were used to evaluate these PS preparations: sera from recipients of a GBS PS vaccine, sera from women receiving a GBS type III PS-tetanus toxoid conjugate vaccine, and sera from nonimmunized healthy women of childbearing age. Estimated antibody concentrations were different depending on the PS preparation used. Using any of the four preparations, we were able to measure ≤0.05 μg of IgG antibody to the GBS type III PS per ml. The specificity of the assay was determined by competitive inhibition with homologous and heterologous PS. The pneumococcal type 14 PS did not inhibit binding of antibody to the native GBS type III PS in sera from adults receiving the GBS PS vaccine or in sera from nonimmunized adults (except serum G9). The pneumococcal type 14 PS inhibited 50% in sera from recipients of GBS type III conjugate vaccine and in serum G9 when GBS type III PS conjugated to biotin or to HSA was used as antigen in ELISA. These data show that free GBS type III PS or PS mixed with mHSA is a sensitive and specific antigen for ELISA and that conjugation can alter the antigenic specificity of a PS.

scholarly journals Fluorescence Spectroscopic Investigation of Competitive Interactions between Quercetin and Aflatoxin B1 for Binding to Human Serum Albumin

Toxins ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 214 ◽  
Author(s):  
Tan ◽  
Chen ◽  
Ma ◽  
Liu ◽  
Zhou ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Aflatoxin B1 ◽  
Elimination Rate ◽  
Protective Effects ◽  
Research Designs ◽  
Speed Up

Aflatoxin B1 (AFB1) is a highly toxic mycotoxin found worldwide in cereals, food, and animal feeds. AFB1 binds to human serum albumin (HSA) with high affinity. In previous experiments, it has been revealed that reducing the binding rate of AFB1 with HSA could speed up the elimination rate of AFB1. Therefore, we examined the ability of quercetin to compete with AFB1 for binding HSA by fluorescence spectroscopy, synchronous spectroscopy, ultrafiltration studies, etc. It was shown that AFB1 and quercetin bind to HSA in the same Sudlow site Ӏ (subdomain IIA), and the binding constant (Ka) of the quercetin-HSA complex is significantly stronger than the complex of AFB1-HSA. Our data in this experiment showed that quercetin is able to remove the AFB1 from HSA and reduce its bound fraction. This exploratory work may be of significance for studies in the future regarding decreasing its bound fraction and then increasing its elimination rate for detoxification. This exploratory study may initiate future epidemiological research designs to obtain further in vivo evidence of the long-term (potential protective) effects of competing substances on human patients.

scholarly journals The Expression of Recombinant Human Serum Albumin in the Mammary Gland of Transgenic Mice

2021 ◽  
Vol 03 (01) ◽  
pp. e30-e37
Author(s):  
Gui-Hua Gong ◽  
Shu Han ◽  
Xiao-Ling Huang ◽  
Li-Ping Xie ◽  
Wei Zhang ◽  
...  
Keyword(s):  
Mammary Gland ◽  
Human Serum Albumin ◽  
Transgenic Mice ◽  
Serum Albumin ◽  
Human Serum ◽  
Regulatory Elements ◽  
Enzyme Linked Immunosorbent Assay ◽  
Alternative Source ◽  
Tissue Specific Promoter ◽  
Polymerase Chain

AbstractHuman serum albumin (HSA) is widely used in the clinic for the treatment of several diseases in large amount each year. With the increasing demands of HSA in clinic and limited blood resource, recombinant HSA (rHSA) is becoming an attractive and alternative source for HSA production. In this study, we aimed to express rHSA in the mammary glands of transgenic mice by using a tissue-specific promoter and other regulatory elements. An rHSA expression vector was constructed bearing the cDNA and first intron of HSA under the control of bovine αs1-casein promoter with a 2 × chicken β-globin insulator in the front. Transgenic mice were generated and reverse transcription polymerase chain reaction showed that rHSA was expressed only in the mammary gland, indicating the tissue specificity of the bovine αs1-casein promoter in directing transgene transcription in transgenic mice. Enzyme-linked immunosorbent assay test showed that rHSA was successfully secreted into the milk of transgenic mice with the highest level at 1.98 ± 0.12 g/L. Our results indicate the ability of the bovine αs1-casein promoter to induce successful expression of rHSA in the mammary gland of transgenic mice.

Sign in / Sign up

Export Citation Format

Share Document